Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Share-based compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 2,624	$ 3,196	$ 4,072	$ 6,675
Research and development
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	929	786	1,907	2,807
General and administrative
Total share-based compensation expense included in the consolidated statements of operations
Total share-based compensation expense	$ 1,695	$ 2,410	$ 2,165	$ 3,868